Blood Pressure News and Research

RSS

Blood Pressure is the force of circulating blood on the walls of the arteries. Blood pressure is taken using two measurements: systolic (measured when the heart beats, when blood pressure is at its highest) and diastolic (measured between heart beats, when blood pressure is at its lowest). Blood pressure is written with the systolic blood pressure first, followed by the diastolic blood pressure (for example 120/80).

New studies: Politicians could do more to tackle the spread of obesity

Politicians could do more to tackle the spread of obesity, a new series of studies suggests. Governments are being urged to encourage better eating habits by supporting financial incentives to enable production of healthier foods, such as subsidised fruit and vegetable production and levies on calorie-rich foods.

15 Jun 2010

New book provides perspective on contributions made by nurses

The quiet actions of unsung heroes from the rainforest of Guatemala to the city streets of Harlem will be celebrated during the 2010 International Year of the Nurse in the new book, Giving through Teaching: How Nurse Educators are Changing the World (Springer Publishing).

14 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.

14 Jun 2010

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the patients for up to five years.

14 Jun 2010

Phase II study results of riociguat for CTEPH and PAH published online

Bayer HealthCare Pharmaceuticals, Inc. today announced that the study "Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study" was published online this week by the European Respiratory Journal. Results of this study to assess the safety, tolerability and the feasibility of individual dose titration of riociguat were previously presented at the 2009 International Conference of the American Thoracic Society.

11 Jun 2010

BMS employees across Canada taking part in third annual Community Action Day

More than 300 employees of Bristol-Myers Squibb Canada will get the day off from their regular work today, but they won't be taking it easy. Instead, they will be joining company retirees and members of their own families in helping out at a variety of community and charitable organizations as part of the company's third annual BMS Community Action Day.

11 Jun 2010

New study to use genetic 'chips' for examining DNA from over 20,000 heart disease patients

New research at the University of Leicester will use the latest genetic techniques to examine DNA from over 20,000 patients with heart disease.

11 Jun 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

Hypertension linked to severity of bipolar disorders

Nearly half of patients hospitalized with bipolar disorder may suffer from hypertension, and the younger a person is diagnosed with the psychiatric condition the more likely they are to develop high blood pressure, according to a recent Michigan State University study.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

Remote monitoring and nurse case management combined improve health of Medicare beneficiaries with CHF

Chronic heart failure (CHF) is one of the most common causes of hospitalization for elderly Americans, and is also one of the nation's most costly conditions to treat.

10 Jun 2010

BMEYE receives European Red Herring Top 100 Award

BMEYE B.V., the innovator of combined noninvasive, beat-to-beat blood pressure and cardiac output monitoring received the prestigious European Red Herring Top 100 Award 2010. Red Herring's Top 100 Europe list has become a mark of distinction for identifying promising new companies and entrepreneurs.

10 Jun 2010

Actelion Pharmaceuticals announces availability of PAH Mobile Reference Guide

Actelion Pharmaceuticals US, Inc. is announcing the availability of the Pulmonary Arterial Hypertension Mobile Reference Guide, the first multimedia smart phone application that provides information on PAH disease, pathology, diagnosis, and treatment guidelines to healthcare professionals.

10 Jun 2010

Gallup-Healthways U.S. Well-Being Report for May 2010

Please be advised that Gallup and Healthways, Inc. today released the Gallup-Healthways Monthly U.S. Well-Being Report for May 2010. The Gallup-Healthways Well-Being Index measurement of U.S. well-being reached 67.4 in May, surpassing the record of 67.0 documented last month and in August of 2009. The record high WBI score in consecutive months suggests ongoing recovery of American well-being despite challenges such as high unemployment.

10 Jun 2010

AACN endorses scientific statement on prevention of TdP

The American Association of Critical-Care Nurses recently endorsed "Prevention of Torsades de Pointes in Hospital Settings," a scientific statement from the American Heart Association, Dallas, and American College of Cardiology Foundation, Washington, D.C.

10 Jun 2010

Sialidase improves nerve regrowth, motor recovery and nervous system function: Researchers

Once damaged, nerves in the spinal cord normally cannot grow back and the only drug approved for treating these injuries does not enable nerve regrowth. Publishing online this week in the Early Edition of the Proceedings of the National Academy of Sciences, researchers at the Johns Hopkins University School of Medicine show that treating injured rat spinal cords with an enzyme, sialidase, improves nerve regrowth, motor recovery and nervous system function.

10 Jun 2010

Patients with BAI can be managed non-operatively with beta-blockade: Researchers

Select patients with blunt aortic injury can be safely managed non-operatively with beta-blockade to lower the heart rate and blood pressure, according to a new study from the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery.

9 Jun 2010

Clinical guidelines for UC emergency medicine physicians

Though guidelines for best treatment practices are common, they are only partially effective without standardized, routine exposure to them in clinical practice, according to a study conducted by University of Cincinnati emergency medicine researchers.

9 Jun 2010

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced Phase 1 data for its novel heart failure Positron Emission Tomography (PET) imaging agent, LMI 1195, which is in development for the evaluation of patients at risk of heart failure or sudden cardiac death.

9 Jun 2010